CD8A and neoplasm: An alternative strategy found to improve the MHC class I presentation of a tumor antigen is the linkage of gamma-tubulin to the HPV oncoprotein in a therapeutic DNA vaccine, which elicited a significant population of tumor-reactive CD8+ T cells in vaccinated mice with HPV + tumors[26].